The US Food and Drug Administration (FDA) approved the antipsychotic drug brexpiprazole (Rexulti) for agitation due to Alzheimer’s disease despite questionable efficacy data and a known higher risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results